Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
Morgan Stanley Maintains Kanzhun(BZ.US) With Buy Rating, Cuts Target Price to $15
Kanzhun Trustee Purchases Another 390,618 Shares Under Post-IPO Scheme, Shares Down 7%
kanzhun-W (02076.HK): Plans to purchase a total of 0.3906 million Class A common shares following the initial public offering.
Gelonghui, on November 25th, announced that kanzhun-W (02076.HK) stated that on November 22, 2024, internal resources will be allocated by the company to purchase a total of 390,618 Class A common shares (equivalent to 195,309 American Depositary Shares) in the open market, and hold these shares in a reits for eligible participants (as defined in the plan), at an average cost of $6.39 per Class A common share (excluding all relevant expenses).
Top Gap Ups and Downs on Thursday: SNOW, ANET, PDD and More
Kanzhun Ltd. Boosts Stakeholder Value With Share Purchase
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}